Proportion of participants with relapse‐free survival at ≥ 12 months · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
Alemtuzumab 24 mg may leads to lower relapse‐free survival compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Sustained disease progression‐free survival · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
Alemtuzumab 24 mg may leads to lower sustained disease progression‐free survival compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Adverse events, including serious adverse events Assessed by: number of participants with ≥ 1 event · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
Alemtuzumab 24 mg showed no clear difference in adverse events, including serious adverse events Assessed by: number… compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 24 mg showed no clear difference in number of participants with at least one adverse event compared with interferon beta 1a (low certainty).
1 finding from 1 review
Number of participants with serious adverse events · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 24 mg showed no clear difference in number of participants with serious adverse events compared with interferon beta 1a (moderate certainty).
1 finding from 1 review
Mean Expanded Disability Status Scale score change from baseline · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis
It is very uncertain whether alemtuzumab 24 mg changes number of participants experiencing treatment discontinuation caused… compared with interferon beta 1a (very low certainty).
1 finding from 1 review
Relapse · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 24 mg may leads to lower number of participants experiencing at least one relapse compared with interferon beta 1a (low certainty).
1 finding from 1 review
Number of participants whose disability worsened · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 24 mg may leads to lower number of participants whose disability worsened compared with interferon beta 1a (low certainty).
1 finding from 1 review
Overall survival: Median length of · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy plus alemtuzumab probably leads to lower overall survival (median 2 years) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).
1 finding from 1 review
Progression‐free survival · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy plus alemtuzumab may leads to lower progression free survival (median 2 years) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (low certainty).
1 finding from 1 review
Treatment related mortality · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy plus alemtuzumab showed no clear difference in treatment related mortality compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).
1 finding from 1 review
Cytomegalovirus reactivation · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy plus alemtuzumab leads to higher cytomegalovirus reactivation compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (high certainty).
1 finding from 1 review
Complete response · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy plus alemtuzumab may leads to higher complete response rate compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (low certainty).
1 finding from 1 review
Infections (all grades) · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy plus alemtuzumab may leads to higher infections (all grades) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (low certainty).
1 finding from 1 review
Serious adverse events · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy plus alemtuzumab showed no clear difference in serious adverse events compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).
1 finding from 1 review
Intervention not reported
Alemtuzumab No direct evidence · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention leads to lower alemtuzumab No direct evidence (high certainty).
1 finding from 1 review
RR 0.57 [0.47, 0.68]
Studies not reported
High
Intervention not reported
Alemtuzumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention may leads to lower alemtuzumab No direct evidence (low certainty).
1 finding from 1 review
RR 0.67 [0.46, 0.99]
Studies not reported
Low
Intervention not reported
Alemtuzumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to lower alemtuzumab No direct evidence (moderate certainty).
1 finding from 1 review
OR 0.39 [0.19, 0.79]
Studies not reported
Moderate
Intervention not reported
Alemtuzumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
It is very uncertain whether the intervention changes alemtuzumab No direct evidence (very low certainty).
1 finding from 1 review
OR 1.52 [0.94, 2.48]
Studies not reported
Very low